Navigation Links
Rigel Announces Third Quarter 2009 Financial Results
Date:11/3/2009

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2009.

For the third quarter of 2009, Rigel reported a net loss of $26.7 million, or $0.70 per share, compared to a net loss of $37.7 million, or $1.03 per share, in the third quarter of 2008. Weighted average shares outstanding for the third quarters of 2009 and 2008 were 38.1 million and 36.6 million, respectively.

Rigel reported total operating expenses of $26.7 million in the third quarter of 2009, compared to $38.7 million in the third quarter of 2008. The decrease in operating expenses was primarily due to the completion of two Phase 2b clinical trials (TASKi2 and TASKi3) in July, a decrease in stock-based compensation expense, and cost savings resulting from our restructuring implemented in the first quarter of 2009. Stock-based compensation expenses decreased from $6.0 million in the third quarter of 2008 to $3.5 million in the third quarter of 2009, primarily due to a higher valuation of options granted in the first quarter of 2008 and full expense recognition of the majority of those options by the end of 2008.

For the nine months ended September 30, 2009, Rigel reported a net loss of $86.5 million, or $2.32 per share, compared to a net loss of $99.0 million in the first nine months of 2008, or $2.76 per share.

As of September 30, 2009, Rigel had cash, cash equivalents and available for sale securities of $156.1 million, compared to $134.5 million as of December 31, 2008. In September 2009, Rigel completed a public offering in which it sold 14,950,000 shares of common stock at a public offering price of $7.25 per share. The aggregate net proceeds of the offering were approximately $101.5 million after ded
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces Presentations at Two Investor Conferences
2. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
3. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
4. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
9. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
10. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
(Date:9/1/2015)... , Sept. 1, 2015 Sargas ... Management (CCM) and Drug Adherence m Health applications ... automate the process of non face-to-face monitoring of ... this new release of our apps, doctors are ... services along with our ONCHIT certified Physician, Pharmacy ...
(Date:9/1/2015)... Sept. 1, 2015   Ivenix Inc. , ... management system, closed on a $42M round of ... Ventures. Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity ... the round. This financing will support the company,s ... Leerink Partners LLC acted as the exclusive placement ...
Breaking Medicine Technology:VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3
... telangiectasia-like disease and Nijmegen breakage syndrome offer ... and cancer vulnerability in people carrying the ... Scientists at St. Jude Children,s Research Hospital ... two related neurological diseases--ataxia telangiectasia-like disease (ATLD) ...
... MannKind Corporation (Nasdaq: MNKD ) ... equivalence of its commercial inhaler to the version of ... deliver AFRESA(TM), MannKind,s ultra rapid acting insulin that recently ... Bioequivalence of Clinical and Commercial Scale Inhalers Study 138 ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... top-five hospital by U.S. News & World Report, to provide breaking news and ... Editorial and marketing groups within OncLive, which provides oncologists resources and information?they need ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... (NAPBS®) has announced that Edge Information Management has been granted continued ... Screening Credentialing Council (BSCC). , “Achieving and maintaining this accreditation takes ...
(Date:9/1/2015)... ... 2015 , ... The Jerry Segal Classic to benefit the patients of Magee ... Club in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by ... services designed to support patients and their families during their time at Magee Rehabilitation ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and analysis of pet vital signs and activity, today announced its integration with ... the most popular and widely-adopted veterinary hospital Practice Management Software packages in the ...
(Date:9/1/2015)... ... , ... With former IBMers among its founding members, Inmar has known the ... 35 years ago. A pilot program begun by the company in 2014 has proved ... intent on pursuing careers in these fields. The program is now open to area ...
Breaking Medicine News(10 mins):Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
... a boost from a surprising source: the 2009 H1N1 pandemic ... strain developed antibodies that are protective against a variety of ... the University of Chicago have found. The results were published ... "Our data shows that infection with the 2009 pandemic ...
... , , Reproductive medicine is one of ... there are announcements of medical ,firsts, new rulings by ... heated debate among practitioners in the field, ethicists, legislators, ... is the forum where more than 9,000 of the ...
... News) -- Race and ethnicity play major roles in whether ... with minorities much less likely to undergo colonoscopies than white ... play: where people live. Research by oncologist Dr. ... Davis Cancer Center found that location makes a big difference ...
... January 10, 2011 -- While most blood tests require shipping a ... days for the results, a new device invented by a team ... just a pinprick of blood in a portable device that provides ... big step in point-of-care diagnostics, where testing can be performed in ...
... News) -- The first study to focus solely on the ... Sept. 11, 2001 attacks on the World Trade Center finds ... of the 3,271 evacuees of the Twin Towers surveyed in ... at least one current post-traumatic stress symptom, while 15 percent ...
... be most useful for clinical decision-making in trials in which ... recent study published online January 7 in The ... has been increasing interest in the value of patient-reported symptom ... secondary endpoints in new trials. Both the World Health Organization ...
Cached Medicine News:Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2Health News:Engineering team invents lab-on-a-chip for fast, inexpensive blood tests 2Health News:Many Survivors of World Trade Center Attacks Suffered PTSD: Study 2Health News:Quality of life measures in breast cancer clinical trials 2
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: